📣 VC round data is live. Check it out!
- Public Comps
- C-Rad
C-Rad Valuation Multiples
Discover revenue and EBITDA valuation multiples for C-Rad and similar public comparables like Fonar, Fractyl Health, SDI Group, Onyx Healthcare and more.
C-Rad Overview
About C-Rad
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
Founded
2004
HQ

Employees
99
Website
Financials (LTM)
EV
$107M
Valuation Multiples
Start free trialC-Rad Financials
C-Rad reported last 12-month revenue of $49M and EBITDA of $7M.
In the same LTM period, C-Rad generated $35M in gross profit, $7M in EBITDA, and $3M in net income.
Revenue (LTM)
C-Rad P&L
In the most recent fiscal year, C-Rad reported revenue of $50M and EBITDA of $6M.
C-Rad is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 13%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
C-Rad Stock Performance
C-Rad has current market cap of $121M, and enterprise value of $107M.
Market Cap Evolution
C-Rad's stock price is $3.66.
C-Rad share price decreased by 2.1% in the last 30 days, and by 5.5% in the last year.
C-Rad has an EPS (earnings per share) of $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $107M | $121M | -1.3% | -2.1% | 29.7% | -5.5% | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialC-Rad Valuation Multiples
C-Rad trades at 2.2x EV/Revenue multiple, and 15.2x EV/EBITDA.
EV / Revenue (LTM)
C-Rad Financial Valuation Multiples
As of June 3, 2026, C-Rad has market cap of $121M and EV of $107M.
C-Rad has a P/E ratio of 39.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified C-Rad Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


C-Rad Margins & Growth Rates
C-Rad decreased revenue by 1% but EBITDA grew by 32% in the last fiscal year.
In the most recent fiscal year, C-Rad reported gross margin of 68%, EBITDA margin of 13%, and net margin of 2%.
C-Rad Margins
C-Rad Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
C-Rad Operational KPIs
C-Rad's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
C-Rad's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
C-Rad's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
C-Rad Competitors
C-Rad competitors include Fonar, Fractyl Health, SDI Group, Onyx Healthcare, JETEMA Co., AVITA Medical, Emvision, Vivani Medical, SANUWAVE Health and Zepp Health.
Most C-Rad public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.0x | - | 5.7x | - | |||
| - | - | (1.3x) | (1.4x) | |||
| 1.7x | 1.5x | 9.2x | 7.7x | |||
| 2.9x | - | 26.0x | - | |||
| 3.7x | - | 24.9x | - | |||
| 2.3x | 2.1x | (4.1x) | (4.8x) | |||
| - | 26.0x | - | (16.9x) | |||
| - | - | (4.1x) | - | |||
This data is available for Pro users. Sign up to see all C-Rad competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout C-Rad
| Who are competitors of C-Rad? | C-Rad main competitors include Fonar, Fractyl Health, SDI Group, Onyx Healthcare, JETEMA Co., AVITA Medical, Emvision, Vivani Medical, SANUWAVE Health, Zepp Health. |
See public comps similar to C-Rad
Lists including C-Rad
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.